Category Archives: Pantheon

Pantheon Awardees 2015

Life Sciences Leadership Awards William H. Rastetter Ph.D. Co-Founder and Chairman of the Board, Receptos, Inc.Bill focuses on making and growing investments in biotechnology. He serves as chairman for each of four San Diego companies: Illumina (ILMN, NASDAQ); Neurocrine Biosciences (NBIX, NASDAQ); Receptos (RCPT, NASDAQ) and Fate Therapeutics (FATE, NASDAQ). He also serves as the … Continue reading Pantheon Awardees 2015

Scott Johnson

Diagnosed in 1976 with MS, Scott Johnson found himself frustrated with the slow progress in research towards finding a myelin repair therapeutic for MS. In 2002, after a 25-year career as a business management consultant and Silicon Valley entrepreneur, MS patient Johnson added patient advocate to his resume and undertook his greatest challenge yet: Developing … Continue reading Scott Johnson

Dr. Jennifer Doudna

CRISPR-Cas9 genome editing technology, largely based on work done from Dr. Jennifer Doudna at Berkeley (and HHMI), is, arguably, the most important and revolutionary technology for molecular biology and model building. Doudna and her lab discovered a protein associated with CRISPR (which are repeating patterns of sequence scattered around the DNA, responsible for helping bacteria … Continue reading Dr. Jennifer Doudna

Congresswoman Jackie Speier

Congresswoman Jackie Speier has lived her entire life inside California’s 14th Congressional District and in April 2008 was elected to represent the district in Congress.  Previously she had served the residents of the San Francisco Peninsula while on the San Mateo County Board of Supervisors and later in the California State Assembly and State Senate. … Continue reading Congresswoman Jackie Speier

Stanley N. Cohen, MD

In November 1973, a paper published in the Proceedings of the National Academy of Sciences by Stan Cohen of Stanford University and Herb Boyer of the University of California fundamentally changed the disciplines of biology, chemistry, and biotechnology. The paper reported the discovery that non-replicating fragments of DNA, the hereditary material of all cells, could … Continue reading Stanley N. Cohen, MD

Cometriq‚Ñ¢ by Exelixis, Inc.

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. The company is focusing its proprietary resources and development efforts on COMETRIQ¬Æ (cabozantinib), its first commercial product. COMETRIQ was nominated for its activity in progressive, metastatic medullary thyroid cancer, a disease state for which, until recently, there … Continue reading Cometriq‚Ñ¢ by Exelixis, Inc.

Tom McFadden

Tom McFadden is passionate about science. And he’s on a quest to get students of all ages excited about it as well. Tom McFadden teaches science through rap with a slightly different approach. His students pen rap battles about conflicts from the history of science. A group of seventh-graders from Oakland, Calif., worked with McFadden … Continue reading Tom McFadden


Ardelyx was founded in 2007 by Dominique Charmot, Ph.D., Peter Schultz, Ph.D. and Jean Frechet, Ph.D., to develop a pipeline of next generation and minimally-absorbed small molecule drugs. Through a radical approach to drug discovery and development, Ardelyx has established a pipeline of novel, first-in-class drugs engineered to correct mineral metabolism imbalance and metabolic disorders. … Continue reading Ardelyx

somo•v™ ABUS (Automated Breast Ultrasound) by U-Systems, a GE Healthcare Company

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world … Continue reading somo‚Ä¢v‚Ñ¢ ABUS (Automated Breast Ultrasound) by U-Systems, a GE Healthcare Company

Portola Pharmaceuticals

Portola Pharmaceuticals is focused on the development of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation.  Portola’s wholly-owned compound, betrixaban, is a novel, oral, once-daily Factor Xa inhibitor in Phase 3 development for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Currently, there is no anticoagulant approved for … Continue reading Portola Pharmaceuticals